Uploaded May 2026 | Updated November 2026, 4 days ago
In this Expert Talk, Dr. Olga Uspenskaya-Cadoz and Dr. James Berry introduce PIONEER-ALS - the first vectorized antibody clinical trial targeting TDP-43 in sporadic ALS.
The session explores the science behind TDP-43 pathology in ALS and how innovative vectorized antibody approaches could potentially transform treatment strategies for sporadic ALS patients. Dr. Olga provides insight into the development of this ground-breaking trial, the rationale behind targeting TDP-43, and what this could mean for the future of ALS therapeutics.
Throughout the discussion, the speakers also highlight the importance of innovation in ALS research, patient participation in clinical trials, and the growing momentum within the ALS therapeutic pipeline.
In this talk, we cover:
• Introduction to the PIONEER-ALS clinical trial
• Understanding TDP-43 and its role in sporadic ALS
• The science behind vectorized antibody therapies
• How this approach differs from traditional ALS treatments
• The future potential of targeted ALS therapeutics
• The importance of clinical research and patient involvement
📲 Download the EverythingALS App
• Google Play: bit.ly/4nXqIYy
• App Store: bit.ly/42tPBmh
Follow EverythingALS:
► Website: everythingals.org
► X: https://x.com/everything_als
► LinkedIn: linkedin.com/company/everythingals
► Facebook: facebook.com/everythingals
► Subscribe for more Expert Talks: youtube.com/@EverythingALS
#ExpertTalk #EverythingALS #ALSResearch #ALSCommunity #ClinicalTrials #SporadicALS #TDP43 #PioneerALS #VectorizedAntibodies #Neurology #ALSTreatment #ALSInnovation #VectorY
In this Expert Talk, Dr. Olga Uspenskaya-Cadoz and Dr. James Berry introduce PIONEER-ALS - the first vectorized antibody clinical trial targeting TDP-43 in sporadic ALS.
The session explores the science behind TDP-43 pathology in ALS and how innovative vectorized antibody approaches could potentially transform treatment strategies for sporadic ALS patients. Dr. Olga provides insight into the development of this ground-breaking trial, the rationale behind targeting TDP-43, and what this could mean for the future of ALS therapeutics.
Throughout the discussion, the speakers also highlight the importance of innovation in ALS research, patient participation in clinical trials, and the growing momentum within the ALS therapeutic pipeline.
In this talk, we cover:
• Introduction to the PIONEER-ALS clinical trial
• Understanding TDP-43 and its role in sporadic ALS
• The science behind vectorized antibody therapies
• How this approach differs from traditional ALS treatments
• The future potential of targeted ALS therapeutics
• The importance of clinical research and patient involvement
📲 Download the EverythingALS App
• Google Play: bit.ly/4nXqIYy
• App Store: bit.ly/42tPBmh
Follow EverythingALS:
► Website: everythingals.org
► X: https://x.com/everything_als
► LinkedIn: linkedin.com/company/everythingals
► Facebook: facebook.com/everythingals
► Subscribe for more Expert Talks: youtube.com/@EverythingALS
#ExpertTalk #EverythingALS #ALSResearch #ALSCommunity #ClinicalTrials #SporadicALS #TDP43 #PioneerALS #VectorizedAntibodies #Neurology #ALSTreatment #ALSInnovation #VectorY

![#ExpertTalk: Targeting an Endogenous Retrovirus as a Therapeutic Approach to ALS
Welcome to another enlightening #experttalk by the EverythingALS, where we delve into cutting-edge research and innovative approaches to combating #ALS (Amyotrophic Lateral Sclerosis).
This discussion dives into the science behind endogenous retroviruses (ERVs), their role in neurodegenerative diseases, and how understanding them could pave the way for innovative treatments for ALS.
🕒 Timestamps
0:00 – Introduction
Meet the speakers and an overview of the session.
3:45 – Understanding Endogenous Retroviruses
What are ERVs, and why are they significant in neurodegenerative diseases?
10:20 – The Role of ERVs in ALS Pathology
How ERVs influence ALS development and progression.
20:15 – Innovative Therapeutic Strategies
Exploring cutting-edge research and treatment possibilities targeting ERVs.
30:50 – Q&A with the Experts
Addressing audience questions and discussing the future of ALS therapies.
40:25 – Closing Remarks
Final insights and takeaways from the session.
👩🔬 About EverythingALS:
EverythingALS is a patient-focused nonprofit organization dedicated to accelerating the discovery of treatments and a cure for ALS through collaboration, innovation, and empowering patients and researchers.
📩 Stay Connected:
Subscribe to our channel and turn on notifications to stay updated on the latest expert talks and research breakthroughs in ALS.
💡 Don’t forget to:
✅ Like this video if you found it helpful!
✅ Subscribe to our channel for more expert talks and updates: [EverythingALS YouTube Channel].
✅ Share this video to spread awareness and support ALS research.
📌 For more resources and to participate in EverythingALS initiatives, visit: everythingals.org
#ALS #EndogenousRetrovirus #ALSResearch #TherapeuticApproach #EverythingALS #Neurodegeneration #ExpertTalk: Targeting an Endogenous Retrovirus as a Therapeutic Approach to ALS](https://i.ytimg.com/vi/5VDgqCW8eOw/mqdefault.jpg)








